Abstract-Increased reactive oxygen species (ROS) generation is implicated in cardiac remodeling in heart failure (HF).
merging data implicates oxidative stress (OS) in heart failure (HF) pathophysiology, contributing to cardiac remodeling, 1,2 mechanoenergetic uncoupling, 3, 4 and depressed myofilament calcium sensitivity. 5, 6 The major enzymatic sources of reactive oxygen species (ROS) in HF are xanthine oxidoreductase (XOR) 7 and nicotinamide adenine dinucleotide 2Ј-phosphate (NADPH) oxidase. 8 Several studies demonstrate XOR upregulation in animal models 4 -7,9,10 and in human dilated cardiomyopathy. 3, 11 Functionally, XOR inhibition (XOI) acutely enhances myocardial mechanical efficiency in both animals and humans with HF. 3, 4 However, whereas NADPH oxidase is implicated in ␣ 1 -adrenoreceptor stimulated hypertrophic signaling 12 and contributes to OS in reperfused hearts, playing a major role in post-myocardial infarction (MI) microvascular obstruction ("no-reflow" phenomenon) 13 and, like XOR, is increased in human HF, 8 the relative contribution of XOR and NADPH oxidase to HF pathophysiology requires further clarification.
A recent series of studies has begun to examine the role of XOR in the cardiac remodeling process. 2, 6, 14 These data contribute to the growing argument implicating XOR as a key source of ROS in evolving HF. Whether inhibition of XOR can elicit reverse remodeling in established dilated cardiomyopathy remains unknown.
Here we tested the hypothesis that cardiac XOR adversely affects cardiac remodeling in established cardiomyopathy in spontaneously hypertensive/HF (SHHF) rats. We show that chronic XOI reverses maladaptive cardiac remodeling through effects on cardiac structure, function, and fetal gene activation in SHHF rats, and that this process occurs independently of NADPH oxidase.
Materials and Methods
An expanded Materials and Methods section is available in the online data supplement at http://circres.ahajournals.org.
Animals and Experimental Protocol
We studied SHHF (nϭ25) rats and their controls, Wistar Kyoto (WKY, nϭ8) rats (Charles River Laboratories Inc, Wilmington, Mass). The SHHF rat is a dilated cardiomyopathy model with hypertension progressing to HF. 15 This model shares common phenotypic features with human HF, [15] [16] [17] including activated fetal gene program 18 and elevated XOR activity. 5 We treated both SHHF and WKY rats with the XOR inhibitor oxypurinol. 19 SHHF and WKY rats were randomly assigned to placebo or treatment with oxypurinol for 4 weeks. Echocardiographic measurements were taken at baseline, 2 weeks, and at the end of the study. In vivo assessment of left-ventricular (LV) hemodynamics was performed at the end of treatment and animals were euthanized. The Institutional Animal Care and Use Committee of The Johns Hopkins University School of Medicine approved all protocols and experimental procedures.
Echocardiographic Measurements
Echocardiographic assessments were performed in WKY and SHHF anesthetized (1% to 2% isoflurane inhalation) rats using a Sonos 5500 Echocardiogram (Philips, Andover, Mass) equipped with a 15-MHz linear transducer. LV anterior wall thickness (AWT), posterior wall thickness (PWT), and end-diastolic (LVEDd) and end-systolic (LVESd) diameters were recorded from M-mode images using averaged measurements from 3 to 5 consecutive cardiac cycles.
LV Hemodynamics
Rats were anesthetized by intraperitoneal injection of ketamine (50 mg/kg) and acepromazine (2 mg/kg). A 2-F micromanometer tipped catheter (SPR-838, Millar Instruments, Houston, Tex) was inserted into the right carotid artery and retrogradely advanced into the left ventricle.
Histopathology
Excised hearts were processed using routine histological procedures. Five-micrometer sections were sliced and stained with hematoxylin/ eosin (H&E). Myocyte width was measured at the level of the nucleus in longitudinally sectioned myocytes. All measurements were determined using NIH Image version 1.30v for Windows.
Measurement of mRNA Expression by Quantitative PCR
Fluorescence based real time quantitative PCR (qPCR) was used to determine the mRNA expression of the following genes: XOR, atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), ␣-myosin heavy chain (␣-MHC), ␤-MHC, and ␣-skeletal actin (␣-SA).
Measurement of XOR Activity
XOR activity was measured using the horseradish peroxidase-linked Amplex Red fluorescence assay (Molecular Probes, Invitrogen Detection Technologies), as described previously. 20 
Oxidative Fluorescent Microtopography Using the Fluorescent Dihydroethidium Probe
Fresh, unfixed heart segments from WKY, WKYϩoxypurinol, SHHF, and SHHFϩoxypurinol rats were frozen and oxidative Figure 1 . Impact of oxypurinol treatment on cardiac remodeling. Echocardiographic changes in WKYϩplacebo (WKYϩP; Ⅺ, nϭ3), WKYϩoxypurinol (WKYϩO; f, nϭ4), SHHFϩplacebo (SHHFϩP; E, nϭ10), and SHHFϩoxypurinol (SHHFϩO; F, nϭ15). A, LV FS is significantly decreased in SHHF rats as compared with WKY but is restored by oxypurinol. LVEDd (B), LVESd (C), and LVM (D) are significantly increased in SHHF rats as compared with WKY. In SHHF, oxypurinol treatment attenuates the increase in all of these parameters. *PϽ0.01 vs WKYϩP and WKYϩO at baseline (0 weeks) and at the end of the study (4 weeks) by 2-way ANOVA; †PϽ0.01 vs SHHFϩP by interaction term (2-way ANOVA); ‡PϽ0.05 by repeated measure within groups. E, Representative LV pressure-volume loops obtained by transient inferior vena cava occlusion in SHHFϩP and SHHFϩO rats demonstrates that oxypurinol treatment leads to decreased LV volume and increased Ees in SHHF rats. fluorescent microtopography was performed using the fluorescent dihydroethidium (DHE) probe, as described previously. 21 
GSH/GSSG Ratio
Determination of the reduced glutathione/glutathione disulfide (GSH/GSSG) ratio was performed by using the glutathione assay kit (Cayman chemical, Ann Arbor, Mich).
Measurement of NADPH Oxidase Activity
NADPH-dependent superoxide (O 2 ⅐Ϫ ) production was measured in LV homogenates (mentioned in XOR activity) using lucigeninenhanced chemiluminescence (␤-NADPH 300 mol/L; at room temperature) on a microplate luminometer (Veritas, Turner Biosystems, Sunnyvale, Calif).
Western Blotting
Whole heart proteins were prepared and Western blots analysis was performed as described. 22 The blots were incubated with primary anti-p47 phox antibody, anti-p22 phox antibody, anti-p67 phox antibody, anti-gp91 phox antibody, anti-sarcoplasmic reticulum Ca ϩ2 ATPase (SERCA2a) antibody, anti-Na ϩ /Ca ϩ2 exchanger (NCX) antibody, anti-phospholamban (PLB) antibody, anti-extracellular signalregulated kinase (ERK) antibody, or anti-pERK antibody.
Statistical Analysis
Data are reported as meanϮSEM. Statistical significance was determined by 1-way or 2-way ANOVA where appropriate, followed by Student-Newman-Keuls post hoc analysis (GraphPad, Instat, and STATA statistical software). The null hypothesis was rejected at PϽ0.05.
Results

Reverse LV Remodeling
Baseline echocardiography revealed that SHHF rats were characterized by decreased FS, with increased LV mass (LVM) and LV internal diameters, as compared with aged matched WKY controls ( Table 1 ). The higher LVM present in SHHF rats was attributable to both increased LVEDd and AWT in comparison to WKY controls (Table 1) .
At the end of 4 weeks of oxypurinol treatment, SHHF treated rats had improved FS (45Ϯ7% versus 27Ϯ5% in untreated SHHF, PϽ0.01), smaller LVEDd (9.7Ϯ0.7 mm versus 11.6Ϯ0.4 mm in untreated SHHF, PϽ0.01) and LVESd (5.6Ϯ0.9 mm versus 8.5Ϯ0.3 mm in untreated SHHF, PϽ0.01), and lower LVM (1790Ϯ217 mg versus 2731Ϯ225 mg in untreated SHHF, PϽ0.01) as compared with untreated SHHF rats ( Figure 1A through 1D ). Placebotreated SHHF rats displayed progressive increases in LVEDd, LVESd, and LVM, with decreased FS. Echocardiographic parameters remained unchanged throughout the period of treatment (placebo or oxypurinol) in WKY.
In vivo hemodynamic analysis revealed increased LV volumes in untreated SHHF rats (PϽ0.05) in comparison to WKY that regressed toward normal after 4 weeks of oxypurinol treatment (Table 2 ). Ejection fraction was smaller (PϽ0.05) in untreated SHHF rats than in WKY and treated SHHF rats. Oxypurinol induced an increase in the slope of the end-systolic pressure-volume relation (Ees) (Pϭ0.01; Table 2 and Figure 1E ). There was no significant difference in LV end-systolic pressure or LV end-diastolic pressure across the groups (Table 2) .
Reverse remodeling was demonstrated at the histological level as oxypurinol treatment regressed the cellular hypertrophy in SHHF rats. The cell width of cardiac myocytes from SHHF untreated rats (10.8Ϯ0.3 m, nϭ35 cells, PϽ0.05) was higher than in both treated (9.8Ϯ0.2 m, nϭ39) and untreated (9.4Ϯ0.2 m, nϭ39) WKY rats. Oxypurinol treatment led to a significant regression in cardiac myocytes width in SHHF rats (9.8Ϯ0.2 m, nϭ34, PϽ0.05) as compared with untreated SHHF rats (Figure 2) . Additionally, the mitogen-activated protein kinase pathway was studied by determining the protein abundance of total and phosphorylated ERK. The pERK/ERK ratio was upregulated in SHHF rats and restored toward normal in the oxypurinol-treated group (Figure 3) .
Ca
2؉ Cycling Proteins
The depressed cardiac performance in SHHF rats was associated with changes in Ca 2ϩ handling proteins. SERCA2a was downregulated (Ϫ0.68-fold), NCX (1.36-fold) was upregulated, and PLB (data not shown) was unchanged in SHHF relative to WKY untreated controls. In oxypurinol-treated SHHF rats, NCX was restored toward normal, whereas SERCA2a had partial restoration (Figure 3 ).
Fetal Gene Program Activity
Hypertrophied and failing hearts are characterized by altered expression of the prototypical members of the fetal gene program. 23 We confirmed upregulated expression of ANP Figure 4 ). Oxypurinol treatment offset the changes in expression of these genes in SHHF rats, with a complete restoration being achieved for BNP and ␤-MHC. Oxypurinol did not change the expression of any of these genes in WKY rats (Figure 4 ).
Oxidative Stress
ROS production was higher in SHHF rats compared with WKY subgroups and oxypurinol treatment restored it toward normal. Oxidative fluorescent microtopography using the fluorescent probe DHE (orange staining), demonstrated elevated O 2 ⅐Ϫ production in SHHF cardiac myocytes as compared with controls ( Figure 5A ). Oxypurinol treatment reduced O 2 ⅐Ϫ production in SHHF, while having no effect in controls ( Figure 5A ). The increase in OS in SHHF rats was further characterized by the decrease in GSH/GSSG ratio (PϽ0.05; Figure 5B ), an index of intracellular OS, in relation to controls. Oxypurinol treatment restored GSH/GSSG ratio in SHHF toward normal, demonstrating reduction in ROS production.
Myocardial XOR Expression and Activity
XOR mRNA was upregulated in SHHF compared with WKY, and oxypurinol treatment did not affect XOR gene expression ( Figure 5C ). This increased expression translated into increased XOR activity in SHHF (54.9Ϯ4.1 mU/g) as compared with WKY (37.2Ϯ1.5 mU/g, PϽ0.05; Figure  5D ). Oxypurinol treatment reduced XOR activity in SHHF toward normal (SHHFϩoxypurinol 35.7Ϯ3.7 mU/g, PϽ0.05 versus SHHF and PϭNS versus WKY) but did not affect XOR activity in WKY (WKYϩoxypurinol 35.8Ϯ2.4 mU/g, PϭNS versus WKY).
NADPH Oxidase Activity and Protein Abundance
We measured NADPH oxidase activity to determine the relative contribution of NADPH oxidase to the increased O 2 ⅐Ϫ production in SHHF rats. NADPH oxidase activity was not increased in SHHF relative to WKY rats (63.22Ϯ8.01 light units/mg ⅐ min Ϫ1 in SHHF versus 56.23Ϯ10.44 light units/mg ⅐ min Ϫ1 in WKY rats, PϭNS; Figure 6A ), and oxypurinol did not affect this activity in either group (52.40Ϯ4.70 light units/mg ⅐ min Ϫ1 in WKYϩoxypurinol and 59.18Ϯ7.98 light units/mg ⅐ min Ϫ1 in SHHFϩoxypurinol, PϭNS; Figure 6A ). NADPH oxidase activity was inhibited by diphenyleneiodonium (DPI), but not by allopurinol or N -nitro-L-arginine methyl ester hydrochloride (L-NAME) in all 4 groups ( Figure 6A ). Interestingly, despite unchanged NADPH activity, cardiac protein abundance of NADPH oxidase subunits (Gp91 phox and P67 phox ) were elevated in SHHF rats in relation to WKY, whereas P22 phox and P47 phox were unchanged ( Figure 6B ). Oxypurinol did not affect the abundance of these subunits.
Discussion
The major findings of this study are that chronic XOI with accompanying reductions in OS favorably affects the natural history of HF, inducing reverse remodeling with restoration of cardiac structure and function while changing the altered patterns of Ca 2ϩ cycling proteins and reversing alterations in Figure 2 . Gross pathology and cell size. A, Gross pathology shows increased LV volumes in SHHF untreated animals (SHHFϩP) that restores toward normal after oxypurinol treatment (SHHFϩO). B, Light microscopy with H&E staining demonstrates LV myocytes from oxypurinol untreated (WKYϩP; nϭ39) and treated (WKYϩO; nϭ39) WKY rats and from SHHFϩP (nϭ35) and SHHFϩO (nϭ34) rats. C, Cellular width is increased in SHHF rats and restores toward normal after oxypurinol treatment. *PϽ0.001 in relation to WKYϩP, †PϽ0.05 in relation to WKYϩO, ‡PϽ0.01 in relation to SHHFϩP.
gene expression in an established model of genetic cardiomyopathy. The beneficial effect of oxypurinol treatment was not secondary to a reduction in afterload between SHHF groups. Furthermore, SHHF rats exhibited increased XOR mRNA expression and activity but unchanged NADPH oxidase activity, and with oxypurinol treatment, XOR activity and O 2 ⅐Ϫ production, but not expression, were reduced toward normal, whereas NADPH oxidase activity was unaltered, suggesting the improved HF phenotype was attributable to reduction in XOR-mediated OS.
There is accumulating data supporting a role for OS in HF, and previous studies have used ischemic 2, 6 or pacing-induced HF 4,9,14 models to demonstrate the importance of OS in HF. In addition to the development of cardiac hypertrophy 23, 24 and post-MI remodeling, 2 OS has been linked to abnormal excitation-contraction coupling, 25, 26 myocyte apoptosis, 27, 28 and ␤-adrenergic downregulation. 9 Recent studies in post-MI models 2, 6, 29 and in a troponin I-truncated mouse model 30 have reported that XOI attenuates LV remodeling and dysfunction, 29, 30 reducing myocardial hypertrophy and interstitial fibrosis, 2 while improving excitation-contraction coupling, cardiac contractility, ␤-adrenergic regulation, and survival. 6, 31 Additionally, using a canine model, our group recently reported improved contractility, reduced systemic vasoconstriction, and improved ventricular vascular coupling, but unaltered preload, by chronic XOI. 14 In the SHHF rats, oxypurinol also resulted in improved contractility, but, unlike in the pacing dog model, 14 LV volumes were reduced. This difference is likely attributable to differences in the models and the fact that the stimulus for cardiac injury was given in an ongoing basis in the previous canine study. Whether XOI can reverse established LV dysfunction in nonischemic dilated cardiomyopathy had heretofore remained unknown. Our observation of substantial reverse remodeling, resulting in better cardiac performance and architecture in treated versus untreated animals, offers unique insights into the mechanisms underlying hypertrophy and HF pathophysiology. Notably, the SHHF rat is a hypertensive model that evolves into a phase of frank LV dysfunction 15 and exhibits symptoms and biochemical changes that parallel those observed in patients with cardiomyopathy and congestive HF. 15, 18 The pattern of NCX upregulation and SERCA2a downregulation observed in SHHF rats is also present in other HF experimental models [32] [33] [34] and in human HF. [35] [36] [37] Unchanged Figure 3 . Protein abundance of ERK and calcium cycling proteins. A, Representative Western blots and group data depicting higher pERK/ERK ratio in SHHF untreated rats (SHHFϩP; nϭ5) compared with WKY untreated controls (WKYϩP; nϭ3) and oxypurinol-treated WKY rats (WKYϩO; nϭ4), which restores toward normal in oxypurinol-treated SHHF rats (SHHFϩO; nϭ7). B, SERCA2a is downregulated (Ϫ0.68-fold) and NCX is upregulated (ϩ1.36 fold) in SHHFϩP in relation to WKYϩP. In SHHFϩO, NCX restored toward normal, whereas SERCA2a had partial restoration. Interestingly, SERCA2a protein abundance in WKYϩO is higher than any of the other 3 groups studied. *PϽ0.05 in relation to WKYϩP, †PϽ0.05 in relation to WKYϩO, ‡PϽ0.05 in relation to SHHFϩP.
PLB expression in SHHF is also observed in other HF models, such as post-MI 38 and in human HF. 39 -41 Oxypurinol restored NCX protein abundance toward normal and partially restored SERCA2a expression. Reduced SERCA2a protein abundance with partial restoration after treatment correlates with depressed systolic cardiac performance in SHHF rats that improves with oxypurinol treatment. The reduced SERCA2a protein abundance could contribute to diastolic dysfunction, but the concomitant increase in NCX likely contributes to improved diastolic Ca 2ϩ removal, as the relaxation time constant () in SHHF rats was close to controls (Table 2) .
XOI is previously shown to improve myocardial energetics. 3, 4, 7, 42 In this regard, HF is associated with decrease of total creatine pool, [pCr], [pCr]/[ATP] ratio, and myocardial total creatine kinase (CK) activity and a fetal shift in CK isoform expression, [43] [44] [45] and HF treatment is accompanied by increase in total CK activity and partially restoration of CK isoform expression. 44, 45 Furthermore, XOR reduces CK activity in vitro, and this effect is reversed by superoxide dismutase 46 and XOI improve ventricular function while normalizing high-energy phosphate ratio in post-MI-induced HF in mice. 42 Therefore, it is possible that improvement in myocardial energetics may be one of the mechanisms for XOI beneficial effects in SHHF rats.
Furthermore, our findings are in line with the known activation of the fetal gene program that occurs in HF. 18, 23 This program consists of a constellation of myocardial genes switched off shortly after birth but selectively reactivated in response to chronic hemodynamic overload, including ANP, BNP, ␣-MHC, ␤-MHC, and ␣-SA. 47 Recent studies using gene therapy approaches targeting calcium cycling genes to alter protein transcription in failing hearts have shown promising results. 26, 48 However, this is the first study investigating the effects of XOI on OS in HF which demonstrates that administration of an orally active compound has effects on gene transcription preventing adverse remodeling while preserving cardiac function in genetically programmed cardiomyopathy. The influence of XOI on the fetal gene program is noteworthy and suggests a direct effect of ROS on the transcription of these genes, as angiotensin-converting enzyme inhibitors and aldosterone antagonists, which also attenuate the progression of myocardial remodeling in SHHF rats, 49 do so without having the transcriptional effects we observed with XOI.
Finally, we evaluated the relative role of XOR and NADPH oxidase in OS in HF. Recently discovered interac- tions between NADPH oxidase and XOR delineate crosstalk regarding ROS generation. NADPH oxidase may maintain endothelial XOR levels, playing a critical role in the conversion of xanthine dehydrogenase to XOR. 50 Also, mice deficient in gp91 phox , continue to exhibit NADPH-dependent O 2 ⅐Ϫ generation and develop pressure overload-induced hypertrophy, suggesting alternative sources of ROS generation. 51 Our findings demonstrate that XOR is an important source of ROS generation in HF, with probably a more relevant role than NADPH oxidase, a contention supported by our physiological observations with regard to increased XOR activity and O 2 ⅐Ϫ production, and unaffected NADPH activity in SHHF rats, despite increased NADPH oxidase subunit abundance. This hypothesis is further supported by the profound effects of XOI on reverse remodeling, Ca 2ϩ cycling protein abundance and fetal gene activation in rat myocardium, which occur with concomitant decreased XOR activity but maintained NADPH oxidase activity. However, the fact that we have not tested a NADPH oxidase inhibitor in vivo limits our conclusion.
The limitations of the present work include the fact that the LV diameters, mass, and FS measured by echocardiography did not reduce beyond baseline levels in SHHF treated animals. LV remodeling persisted in untreated animals but was halted in treated animals according to echocardiographic parameters. However, the observations that XOI-treated SHHF rats had LV volumes measured by conductance catheter and myocyte size similar to WKY controls does support Figure 5 . Superoxide production and XOR expression and activity. A, Oxidative fluorescent microtopography using the fluorescent probe DHE demonstrates increased staining in SHHF untreated rats (SHHFϩP; orange-staining nuclei) relative to untreated WKY (WKYϩP), indicating increased OS in SHHF hearts (top). Oxypurinol treatment in SHHF (SHHFϩO) shows decreased staining while having no effect in WKY (WKTϩO; bottom). B, Reduced GSH/GSSG ratio in SHHFϩP in relation to both WKYϩP and WKYϩO suggests increased OS in SHHF rats. Oxypurinol treatment restores GSH/GSSG ratio toward normal in SHHF rats. C, mRNA expression is increased in SHHFϩP (nϭ5) rats as compared with WKYϩP (nϭ3, PϽ0.05) and is not affected by oxypurinol (SHHFϩO; nϭ7). D, XOR activity measured by Amplex Red assay is increased in SHHFϩP (nϭ5) rats as compared with WKYϩP (nϭ3). Oxypurinol treatment restores the activity in SHHFϩO rats (nϭ4), whereas it does not have any effect in WKYϩO (nϭ4). *PϽ0.05 vs WKYϩP, †PϽ0.05 vs WKYϩO, ‡PϽ0.05 vs SHHFϩO. Figure 6 . NADPH oxidase activity and protein abundance in LV homogenates. A, NADPH activity measured by lucigeninenhanced chemiluminescence assay remains unchanged in SHHFϩP rats (nϭ7) as compared with WKYϩP (nϭ3), and oxypurinol treatment does not affect the activity in both WKYϩO (nϭ4) and SHHFϩO (nϭ5) rats (PϭNS). NADPH oxidasedependent O 2 ⅐Ϫ production is abolished by DPI in all 4 groups (*PϽ0.01) but not by allopurinol (Allo) or L-NAME. B, Protein abundance of NADPH oxidase subunits Gp91 phox and P67 phox is increased to similar extent in treated (nϭ4) and untreated (nϭ3) SHHF rats in relation to WKY (nϭ3; * PϽ0.01), whereas P22 phox and P47 phox are unchanged.
a reverse remodeling effect. Additionally, it remains unclear whether the changes in either the activation of the fetal gene program or calcium cycling protein abundance preceded changes in LV structure and function.
In summary, we have demonstrated that chronic XOI with oxypurinol causes reverse LV remodeling, improves function, alters Ca 2ϩ cycling protein abundance, and restores molecular markers of the fetal gene program toward normal in SHHF rats. Furthermore, we show that improved HF phenotype is attributable to XOR-mediated reduced OS and that the contribution of NADPH oxidase is relatively minimal. These data support the idea that that XOR is a primary source of ROS generation in failing hearts and that its upregulation contributes to maladaptive cardiac hypertrophy, directly participating in the progression of LV failure.
